1
artículo
Publicado 2020
Enlace
Enlace
Introduction and aims Several non-invasive scoring systems have been developed and validated worldwide to predict the risk of liver fibrosis in nonalcoholic fatty liver disease (NAFLD). However, information about the performance of these systems in Latin American populations is scarce. Our aim was to evaluate the performance of the Hepamet Fibrosis Score, Fibrosis-4 (FIB-4) and the NAFLD Fibrosis Score (NFS) in a mixed Latin American group of NAFLD patients. Methods Clinical, laboratory and liver biopsy data collected from 379 biopsy-proven NAFLD patients from Latin American tertiary health centers were reviewed. Histological fibrosis stages were classified using the Kleiner score. Accuracy was determined, and new fibrosis score thresholds were calculated to better compare the performances of non-invasive tests and to explore their usefulness in excluding fibrosis. Results The distributi...
2
artículo
Publicado 2013
Enlace
Enlace
La hepatitis C es una causa común de enfermedad hepática en etapa terminal, y la principal indicación para el trasplante de hígado en América Latina. El tratamiento de los pacientes infectados con hepatitis C mejora los resultados considerablemente a largo plazo como la mortalidad. La respuesta viral sostenida se alcanza en cerca del 50% de los pacientes con el tratamiento previo basado en interferón pegilado y ribavirina. Recientemente, se dispone de nuevos medicamentos que aumentan significativamente la respuesta viral sostenida, cambiando el estándar de atención a la terapia triple. Esta guía proporciona al profesional de la salud de Latinoamérica un marco de referencia para el manejo de pacientes con infección crónica por hepatitis C.
3
artículo
Publicado 2014
Enlace
Enlace
La infección crónica por el virus de la hepatitis C (VHC) es una preocupación importante para la salud pública. Está estimado que viven actualmente con hepatitis C crónica más de 185 millones de personas, aproximadamente el 3% de la población mundial, uno de cada tres de esas personas desarrolla cirrosis y carcinoma hepatocelular. La prevalencia de la infección crónica por el virus de la hepatitis C en América Latina es heterogénea. En el presente artículo se plasman recomendaciones frente esta problemática global: políticas públicas para enfrentar el virus de hepatitis C, sugerencias en el diagnóstico de hepatitis C crónica, estadificación hepática, tratamiento de hepatitis C crónica, tratamiento de hepatitis aguda en adultos, tratamiento de cirrosis, tratamiento de personas con coinfección del virus de hepatitis C y VIH, tratamiento de personas con hepatitis C y f...
4
artículo
Publicado 2013
Enlace
Enlace
Hepatitis C is a common cause of end-stage liver disease, and the main indication for liver transplantation in Latin America. Treatment of hepatitis C infected patients improves important long-term outcomes as mortality. Sustained viral response is reached in near 50% of patients with the previous management based in pegylated interferon and ribavirin. Recently new drugs were available increasing sustained viral response significantly, changing the standard of care to triple therapy. This guidelines provides a framework for practitioner in Latin America, to the management of patients with hepatitis C chronic infection.
5
artículo
Publicado 2020
Enlace
Enlace
Non-alcoholic fatty liver disease (NAFLD) currently represents an epidemic worldwide. NAFLD is the most frequently diagnosed chronic liver disease, affecting 20–30% of the general population. Furthermore, its prevalence is predicted to increase exponentially in the next decades, concomitantly with the global epidemic of obesity, type 2 diabetes mellitus (T2DM), and sedentary lifestyle. NAFLD is a clinical syndrome that encompasses a wide spectrum of associated diseases and hepatic complications such as hepatocellular carcinoma (HCC). Moreover, this disease is believed to become the main indication for liver transplantation in the near future. Since NAFLD management represents a growing challenge for primary care physicians, the Asociación Latinoamericana para el Estudio del Hígado (ALEH) has decided to organize this Practice Guidance for the Diagnosis and Treatment of Non-Alcoholic F...
6
artículo
Publicado 2023
Enlace
Enlace
BACKGROUND & AIMS: Genetic ancestry or racial differences in health outcomes exist in diseases associated with systemic inflammation (e.g., Covid-19). This study aimed to investigate the association of genetic ancestry and race with acute-onchronic liver failure (ACLF), which is characterized by acute systemic inflammation, multi-organ failure and high risk of short-term death. METHODS: This prospective cohort study analyzed a comprehensive set of data including genetic ancestry and race, among several others, in 1274 patients with acutely decompensated cirrhosis (ADC) who were nonelectively admitted to 44 hospitals from 7 Latin American countries. RESULTS: 395 (31.0%) had ACLF of any grade at enrollment. Patients with ACLF had higher median percentage of Native American genetic ancestry and lower median percentage of European ancestry than patients without ACLF (22.6% vs 12.9% and 53.4%...
